[{"id":"d413d963-d011-4e09-b546-c83cb27d35a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02159950","created_at":"2021-01-18T10:03:14.468Z","updated_at":"2024-07-02T16:35:49.478Z","phase":"Phase 2","brief_title":"Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer","source_id_and_acronym":"NCT02159950","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provenge (sipuleucel-T) • tasquinimod (ABR-215050)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2023-04-27"},{"id":"fa8d1227-0be1-4356-9dd2-d964f9a93d51","acronym":"","url":"https://clinicaltrials.gov/study/NCT01743469","created_at":"2021-01-18T07:38:26.960Z","updated_at":"2024-07-02T16:37:04.172Z","phase":"Phase 2","brief_title":"A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers","source_id_and_acronym":"NCT01743469","lead_sponsor":"Ipsen","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tasquinimod (ABR-215050)"],"overall_status":"Completed","enrollment":" Enrollment 201","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2019-01-08"}]